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Efficacy of seven and fourteen days of
antibiotic treatment in uncomplicated
Staphylococcus aureus bacteremia (SAB7):
study protocol for a randomized controlled
trial
Louise Thorlacius-Ussing1* , Christian Østergaard Andersen2, Niels Frimodt-Møller3, Inge Jenny Dahl Knudsen2,
Jens Lundgren4 and Thomas Lars Benfield1
Abstract
Background: Staphylococcus aureus bacteremia (SAB) is frequently encountered in the hospital setting, and current
guidelines recommend at least 14 days of antibiotic treatment for SAB in order to minimize risks of secondary deep
infections and relapse. However, evidence to support these treatment recommendations remains scarce. Patients
with uncomplicated SAB are known to have a low of risk of recurrence and death. Reducing treatment length in
uncomplicated SAB would reduce the total consumption of antibiotics, duration of hospital admission, and
potentially the risk of adverse events. With SAB7 we seek to determine if 7 days of antibiotic treatment in patients
with uncomplicated SAB is non-inferior to 14 days of treatment.
Methods/design: The study is designed as a randomized, non-blinded, non-inferiority, multicenter interventional
study. Primary measure of outcome will be 90-day survival without clinical or microbiological failure to treatment or
relapse. Secondary outcomes include the prevalence of severe adverse effects, in particular secondary infection with
Clostridium difficile, all-cause mortality, as well as public health related costs. Patients identified with uncomplicated
SAB who have received 7 days of protocol-approved antibiotics will be eligible for inclusion and randomized 1:1 in
two parallel arms to either (i) discontinue antibiotic treatment at day 7 or (ii) to continue antibiotic treatment for a
total of 14 days. Main exclusion criteria include signs of complicated SAB, such as the presence of secondary deep
infections, persistent bacteremia, and implantable devices. Patients are followed for 6 months with clinical examinations,
consecutive blood tests, and registration of adverse events. A total of 284 patients are to be included at ten centers across
Denmark. The primary endpoint will be tested with a statistical non-inferiority margin of 10 percentage points.
Discussion: SAB 7 will determine if 7 days of antibiotic treatment in patients with uncomplicated SAB is sufficient and
safe. Results of the study will provide important knowledge on optimized SAB management and could potentially modify
the current treatment recommendations.
Trial registration: ClinicalTrails.gov, H-17027414. Registered on May 2, 2018. The Danish Medicines Agency (EudraCT),
2017–003529-13. Registered on October 30, 2017.
Keywords: Randomized controlled trial, Staphylococcus aureus bacteremia, Bloodstream infection, Treatment duration,
Short-course therapy, Uncomplicated Staphylococcus aureus bacteremia
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Background
Background
The extensive use of antibiotics worldwide is closely re-
lated to the increasing issues of antimicrobial resistance
and antibiotic-associated infections [1, 2]. Long-course
antibiotic treatment, as used for blood stream infections,
plays a critical role in this context.
Staphylococcus aureus is one of the most frequent
causes of bacterial infections in skin, bone, tissue, and
blood, with bacteremia being one of the most severe pre-
sentations. In Denmark the incidence is around 25 per
100,000 population, corresponding to approximately 1800
cases of S. aureus bacteremia (SAB) each year [3–5]. SAB
is often associated with severe complications, such as sec-
ondary deep infections, and a reported mortality rate of
20–25% [5]. However, nearly half of cases are classified as
uncomplicated infections associated with a significantly
lower risk of relapse and death [6, 7]. Uncomplicated SAB
is partly due to in-hospital infections related to invasive
procedures and the use of peripheral and central venous
catheters, as well as community-acquired skin and soft tis-
sue infections [8, 9].
Present international and Danish guidelines recom-
mend a standard treatment regimen of a minimum of
14 days of intravenous antibiotics for SAB [6]. However,
these recommendations are based on only a few ran-
domized clinical studies and, to a greater extent, on indi-
vidual expert opinion [10]. Only one minor clinical trial
has evaluated the length of treatment in SAB, and this
found no significant differences in outcome between 2
and 4 weeks of treatment [11]. It is known from
case-based studies that 10–14 days of treatment in un-
complicated SAB are associated with few secondary
complications and failure to treat events [12–15]. Inter-
estingly, three observational studies showed that 7 days
of treatment in simple catheter-associated SAB were ef-
fective and not associated with a higher risk of recur-
rence if the focus of the infection was eradicated. In all
reported cases, follow-up blood cultures were negative
and the patients showed no clinical or biochemical signs
of adverse events or complications [6, 7, 16]. However,
present evidence regarding length of treatment for SAB
is limited and further research in the area could poten-
tially modify current clinical practice.
Hypothesis and aims
We hypothesize that 7 days of antibiotic treatment in
uncomplicated SAB is non-inferior to 14 days of
treatment.
We primarily seek to compare 7 and 14 days of anti-
biotic treatment in patients with uncomplicated SAB in
terms of mortality and the prevalence of microbiological
and clinical failure to treat and recurrence within 90 days
of diagnosis.
The study aims to explore the possibility of reducing
the consumption of antibiotics, as well as shortened hos-
pital admission, and thereby potentially decrease the risk
of adverse events and microbial resistance development.
Primary and secondary outcomes
Primary outcome
– The primary outcome is 90-day survival without
clinical or microbiological failure to treatment or re-
lapse in patients treated with 7 days versus 14 days
of antibiotic therapy
Secondary outcomes
– All-cause mortality on days 14, 28, 90, and 180
– Microbiological failure to treatment
– Microbiological relapse
– Clinical failure to treatment
– Desirability of outcome ranking (DOOR)
– Hospital admissions during follow-up
– Severe adverse events grade ≥ 3
– Acute renal injury
– Clostridium difficile infection
– Infection with multidrug-resistant organisms
– Health-associated costs associated the treatment
lengths
Methods/design
Design and randomization
The study is a randomized, non-blinded, non-inferiority,
interventional study. Confirmation of study eligibility
will be performed by entering key variables into a
web-based program (REDCap) with subsequent auto-
matic patient randomization into two parallel arms (ratio
1:1): treatment regimens of 7 or 14 days, respectively.
Randomization lists will be generated centrally in ran-
dom blocs and stratified according to catheter-associated
infections as well as center/hospital. For a detailed de-
scription of the items included in the SAB7 study proto-
col, please see the SPIRIT table in Additional file 1.
Ethics and regulatory considerations
The study has been approved by the relevant regulatory
authorities, including The Danish Medicines Agency
(EudraCT 2017–003529-13), Research Ethics Committee
of the Capital Region of Denmark (H-17027414), and The
Danish Data Protection Registry (ID AHH-2017-086,
I-Suite no.: 05891). The study will be conducted according
to ICH-GCP (guidelines for Good Clinical Practice
(GCP)) and monitored by GCP units in Denmark. In-
formed consent is obtained from all study participants.
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Setting
The following ten hospitals, representing all five regions
of Denmark, will be invited to participate in the study:
Hvidovre Hospital, Rigshospitalet, Herlev Hospital,
Hillerød Hospital, Roskilde Hospital, Odense University
Hospital, Kolding Hospital, University Hospital of Aarhus,
Herning Hospital, and University Hospital of Aalborg.
Study population
Uncomplicated SAB is defined according to the guide-
lines of the Infectious Disease Society of America [17].
Briefly, patients are required to be free of signs of infec-
tious endocarditis and have a negative follow-up blood
culture, a physical examination without signs of meta-
static foci, absence of fever 48–72 h after initiation of ap-
propriate antibiotic therapy, and no implantable devices.
Prosthetics in joint and bones implanted > 6months
prior to SAB will be accepted if the patients show no
clinical signs of infection involving the prosthetics. In-
clusion and exclusion criteria are listed in detail in
Table 1. Eligible patients must fulfill all of the inclusion
and none of the exclusion criteria (Fig. 1). Cases are
identified through the respective departments of micro-
biology and infectious diseases at each center. All partic-
ipants are hospitalized at enrollment.
Treatment
Patients will receive antibiotic treatment adhering to
local and national guidelines as well as according to the
susceptibility of the respective isolate. Participation in
the study will only affect treatment duration and will
have no influence on the choice of treatment with re-
spect to type and dose of antibiotic agent. Patients enter-
ing the study have already received 7 days of antibiotic
treatment. According to randomization, patients will (i)
discontinue antibiotic treatment at day 7 or (ii) continue
antibiotic treatment for a total of 14 days. Antibiotics
considered appropriate for empiric treatment of SAB are
listed in Table 2.
Assessment and data collection
A summary of collected data is presented in Fig. 3. Study
participants will be followed by doctors at the respective
centers for 6 months after the SAB diagnosis (Figs. 2
and 3). Hospitalized patients will be assessed in accord-
ance with the study protocol and local hospital stan-
dards. Day 0 is defined as the initiation of antibiotic
therapy with antimicrobial effects against SAB (Fig. 1).
Days 1–6 serve as a screening period to determine study
eligibility. Eligible patients will be included in the trial
and randomized at day 7. To evaluate outcome efficacy
patients will undergo three follow-up examinations on
day 14 and weeks 12 and 26, respectively. The first
follow-up visit will consist of a physical examination,
whereas the second and third follow-up visits will con-
sist of a clinical consultation or a standardized telephone
interview (Fig. 2). In addition to the scheduled follow-up
visits, patients will at discharge be thoroughly instructed
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age > 18 years • Persistence of S. aureus bacteremia before randomization (S. aureus positive
follow-up blood culture obtained within 48–120 h of the first positive blood
culture)
• Blood culture positive for Staphylococcus aureus • Polymicrobial infection
• Antibiotic treatment with antimicrobial activity to S. aureus
administrated within 12 h of the first positive blood culture
• Antibiotic treatment with no antimicrobial activity to S. aureus administered
more than 12 h after the first positive blood culture
• Temperature < 37,5 °C at randomization • Endocarditis or other intracardiac infection demonstrated with transthoracic
or transesophageal echocardiography
• S. aureus negative follow-up blood culture obtained 48–120 h
after microbiologically verified SAB
• Previous history of endocarditis
• Patients written consent obtained • Pacemaker or other intracardiac implant
• Failure to remove a likely focus of infection, such as central venous catheter,
within 72 h of the first positive blood culture
• Vascular grafts
• Pneumonia or infection involving bone, joints, or prosthetics
• Previous bone/joint infection
• S. aureus infection within the last 90 days
• Pregnancy or breastfeeding
• Neutropenia (blood neutrophils < 1.0 × 109/l)
• Untreated cancer
• Chemotherapy within 90 days.
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on contacting the treating physician if they develop
symptoms or fever at any time between follow-up visits.
Any signs of fever must lead to a clinical evaluation,
blood testing, and blood culture. Follow-up data and la-
boratory tests are described in Fig. 3. Additional
follow-up regarding comorbidity and other clinical vari-
ables is conducted by the use of hospital and national
databases. All data are registered in an electronic case
report form.
Outcome measures
Primary outcome
Data regarding the composite primary endpoint, 90-day
survival without clinical or microbiological failure to
treatment or relapse, will be acquired through patient
interviews, clinical consultation, and microbiological
tests as well as hospital and national administrative
registries.
Microbiological failure to treatment is defined as
verified S. aureus, of the same genotype (based on
spa type) as the initial infection, less than 7 days after
treatment termination.
Microbiological SAB relapse is defined as demon-
stration of the same S. aureus genotype as the initial
infection more than 7 days after treatment termin-
ation, demonstrated by molecular-based typing [18,
19]. Verification of S. aureus as the infectious agent
in question will be performed by microbiological ana-
lysis of biological material such as blood, synovial
fluid, etc.
Fig. 1 Timeline of SAB7
Table 2 Acceptable empiric antibiotic treatment of SAB
Antibiotic Form * (oral or iv) Standard dose * Frequency * Dose adjustment *
Piperacillin + tazobactam (MSSA) IV 4 g + 0.5 g Every 8 h Renal impairment
Dicloxacillin (MSSA) Oral or IV 1 g Every 6 h Weight
Flucloxacillin (MSSA) Oral or IV 1 g Every 6–8 h Renal impairment
Cloxacillin (MSSA) Oral or IV 1 g Every 6–8 h Renal impairment
Cefuroxim (MSSA) IV 750 mg
1.5 g
Every 6 h
Every 8 h
Renal impairment
Clindamycin (MSSA + MRSA) Oral 600 mg Every 6–8 h –
Macrolides (MSSA)
Claritromycin Oral or IV 500 mg Every 12 h Renal and liver impairment
Vancomycin (MSSA + MRSA) IV 1 g IV Every 12 h Renal impairment
Se- vanco
Linezolid (MRSA + MSSA) Oral or IV 600 mg Every 12 h –
Rifampicin (MSSA) Oral 300–600mg Every 8 h –
Meropenem (MSSA) IV 1–2 g Every 8 h Renal impairment
Moxifloxacin (MSSA) Oral or IV 400 mg Every 24 h –
Aminoglycosides (MSSA)
-Gentamycin IV 5 mg/kg Every 24 h Renal impairment
*Standard recommendations
IV intravenous, MSSA methicillin-sensitive Staphylococcus aureus, MRSA methicillin-resistant Staphylococcus aureus, Se-vanco serum-vancomycin
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Clinical failure to treatment or relapse is defined as
initiation of anti-staphylococcal therapy for more than
48 h on suspected clinical recurrence.
Data on vital status during follow-up are obtained
from local hospital registries and the Danish Civil Regis-
tration System.
Data regarding the primary endpoint will be evaluated
and determined by an independent committee (Endpoint
Review Committee) blinded to randomization.
Secondary outcome
The components of the composite primary outcome
will also be assessed separately as a secondary out-
come, which is defined as described above. Additional
secondary objectives are overall survival at days 14,
28, and 180 and the presence of severe adverse
events, including the prevalence of C. difficile-asso-
ciated diarrhea, infection with a multidrug-resistant
organism and grade 3 or above adverse events as defined
elsewhere (https://ctep.cancer.gov/protocoldevelopment/
electronic_applications/ctc.htm). The prevalence of ad-
verse events will be derived from patient interviews and
laboratory reports, including, if relevant, documentation
of the microbiological method applied for verification of
C. difficile. Additionally, follow-up blood tests will also be
used to assess adverse events by screening for possible
antibiotic-related affects on, e.g., liver and kidney function.
Acute kidney injury is defined as a 1.5-fold increase in
plasma creatinine or a 25% decrease of estimated glom-
erular filtration rate (GFR).
Our definition of multidrug-resistant organisms will
rely on identification of resistant bacteria in a clinical
Fig. 2 Flowchart of SAB7
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specimen obtained only from a patient with a clinical in-
fection. As such, routine screening of asymptomatic in-
dividuals to identify potential colonization with a
resistant microorganism will not be performed.
To exclude potential effects of concomitant medical
therapy not related to SAB treatment, additional anti-
biotic consumption within the study period is registered.
Public health-related costs will be estimated from a
general consideration of the expenses associated with
hospitalization for SAB.
Statistics
Pilot phase
Based on local and national databases, we expect a fail-
ure to treat and relapse rate of < 5% for patients with
uncomplicated SAB alive at day 7 and a 90-day all-cause
mortality rate of approximately 7%, corresponding to a
recovery rate of 88% [20]. However, available data on re-
currence and death in this select group of patients is
sparse. Consequently, an adaptive trial design is used in
which the event rate is reassessed and the sample size
and the non-inferiority margin adjusted if appropriate.
The reassessment will occur at the second interim ana-
lysis when 100 patients have entered the study and com-
pleted 90 days of follow-up. Reassessment after the
second interim analysis may lead to one of four changes
to the study: 1) sample size and non-inferiority margin
will remain unchanged because the event rate is 12%; 2)
sample size and non-inferiority margin will be lowered
because the event rates is < 12%; 3) sample size will be
Fig. 3 Data collection and follow-up for patients enrolled in SAB7
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increased because the event rate is > 12% while the
non-inferiority margin will remain unchanged; or 4) the
trial will be terminated due to safety concerns.
The regulatory authorities will be informed of the re-
sult of the pilot phase and interim analysis and potential
adjustments to sample size.
Sample size
Non-inferiority is defined as a difference in primary end-
point of up to 10%. Assuming a treatment response of
88%, statistical power of 80%, a statistical significance
level of 5% and a 2% loss to follow-up rate, 284 random-
ized patients are require in order to exclude predefined
difference in the two groups. Sample size was estimated
using simulation, with the assumption of a 12% failure
in both groups and a non-inferiority margin of 10%.
Interim analysis
We will perform two interim analyses when 30 and 100
patients have completed the study, respectively. This
serves to evaluate the primary and secondary endpoints
and potential adverse events by an independent data and
safety monitoring board (DSMB).
The Haybittle-Peto method is applied to demonstrate
overwhelming differences between the two treatment
groups that necessitate premature termination of the
trail. A significant p value of 0.001 in the interim ana-
lyses will correspond to a p value of 0.05 in the final
analysis.
Discussion
SAB represents a persistent challenge in bacterial infec-
tions. Research in this field has until now mainly focused
on identifying risk factors associated with secondary
complications, handling the increasing frequency of
methicillin resistant Staphylococcus aureus (MRSA) in-
fections, and, to a lesser extent, improving the present
treatment strategies. The SABATO trail is currently in-
vestigating if early oral switch therapy is safe and effect-
ive for patients with low-risk SAB [21]. Even though this
study may address issues with long-course intravenous
treatment, results will not affect the overall consumption
of antibiotics nor treatment length. To the best of our
knowledge, this is the first randomized clinical study to
assess reduced treatment length in SAB and the efficacy
of 7 days of treatment. We chose SAB-associated death,
microbiological and clinical failure to treat, and recur-
rence as the primary endpoint, as we feel this is the most
accurate measure of the effectiveness of the treatment.
SAB7 will, regardless of the outcome, provide import-
ant information on optimized treatment of patients with
uncomplicated SAB. At best, the study will provide evi-
dence that a reduction in treatment length in uncompli-
cated SAB is sufficient and safe. If so, this may lead to a
paradigm shift in the treatment of patients with uncom-
plicated SAB. Results of SAB7 will potentially improve
future treatment in several ways. Reducing treatment
length in uncomplicated SAB could induce earlier
discharge from the hospital, decreased risk of
hospital-acquired infections, decreased risk of severe ad-
verse events, and an increased quality of life. Addition-
ally, from a national and international perspective,
decreasing the consumption of antibiotics will play an
important role in preventing resistance development and
secure future antimicrobial treatment.
Trial status
The first patient was recruited on July 20, 2018. Recruit-
ment is expected to be completed in May 2021.
Additional file
Additional file 1: SPIRIT 2013 checklist. (DOC 122 kb)
Abbreviations
ALAT: Alanine amino transferase; CRP: C-reactive protein; DSMB: Data and
Safety Monitoring Board; GCP: Good clinical practice; ICH: International
Conference of Harmonization; LDH: Lactate dehydrogenase;
MRSA: Methicillin resistant Staphylococcus aureus; MSSA: Methicillin sensitive
Staphylococcus aureus; SAB: Staphylococcus aureus bacteremia
Acknowledgements
Haakon Sandholt and Steen Ladelund for statistical support.
Funding
Financial cost is held by public funds form Danish Regions and The Ministry
of Health. Funders have no role in the design of the study, data collection,
data analysis, or preparation of the final manuscript.
Availability of data and materials
Not applicable.
Authors’ contributions
The research question of the study was conceived by TB. TB obtained
funding for the study and participated in the design of the study and the
preparation of the protocol. LU drafted the protocol, coordinated the study,
and participated in the study design. JL, NF, CA, and IK participated in the
design of the study. All authors have read and approved the protocol in its
present form.
Ethics approval and consent to participate
We require both verbal and written consent from all eligible patients prior to
inclusion in the study. The study has been approved by the Research Ethics
Committee of the Capital Region of Denmark, Kongens Vaenge 2, Hilleroed,
3400 Denmark (H-17027414).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Thorlacius-Ussing et al. Trials          (2019) 20:250 Page 7 of 8
Author details
1Department of Infectious Diseases, Hvidovre Hospital, Copenhagen
University Hospital, Kettegaard Alle 30, 2650 Hvidovre, Denmark.
2Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen
University Hospital, Hvidovre, Denmark. 3Department of Clinical Microbiology,
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
4Department of Infectious Diseases, Rigshospitalet, Copenhagen University
Hospital, Copenhagen, Denmark.
Received: 27 August 2018 Accepted: 4 April 2019
References
1. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic
use in Europe and association with resistance: a cross-national database
study. Lancet. 2005;365(9459):579–87.
2. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al.
Burden of Clostridium difficile infection in the United States. N Engl J Med.
2015;372(9):825–34.
3. Thorlacius-Ussing L, Sandholdt H, Larsen AR, Petersen A, Benfield T. Age-
Dependent Increase in Incidence of Staphylococcus aureus Bacteremia,
Denmark, 2008–2015. Emerg Infect Dis. maj 2019;25(5).
4. Mejer N, Westh H, Schønheyder HC, Jensen AG, Larsen AR, Skov R, et al.
Stable incidence and continued improvement in short term mortality of
Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect
Dis. 2012;17(12):260.
5. Benfield T, Espersen F, Frimodt-Møller N, Jensen AG, Larsen AR, Pallesen LV,
et al. Increasing incidence but decreasing in-hospital mortality of adult
Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol
Infect. 2007;13(3):257–63.
6. Fowler VG, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, et al.
Outcome of Staphylococcus aureus bacteremia according to compliance
with recommendations of infectious diseases specialists: experience with
244 patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 1998;27(3):478–86.
7. Blyth CC, Darragh H, Whelan A, O’Shea JP, Beaman MH, McCarthy JS.
Evaluation of clinical guidelines for the management of Staphylococcus
aureus bacteraemia. Intern Med J. 2002;32(5–6):224–32.
8. Nissen JL, Skov R, Knudsen JD, Ostergaard C, Schonheyder HC, Frimodt-
Moller N, et al. Effectiveness of penicillin, dicloxacillin and cefuroxime for
penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective,
propensity-score-adjusted case?control and cohort analysis. J Antimicrob
Chemother. 2013;68(8):1894–900.
9. Rasmussen JB, Knudsen JD, Arpi M, Schonheyder HC, Benfield T, Ostergaard
C. Relative efficacy of cefuroxime versus dicloxacillin as definitive
antimicrobial therapy in methicillin-susceptible Staphylococcus aureus
bacteraemia: a propensity-score adjusted retrospective cohort study. J
Antimicrob Chemother. 2014;69(2):506–14.
10. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME, et
al. Clinical management of Staphylococcus aureus bacteraemia. Lancet
Infect Dis. 2011;11(3):208–22.
11. Rahal JJ, Chan YK, Johnson G. Relationship of staphylococcal tolerance,
teichoic acid antibody, and serum bactericidal activity to therapeutic
outcome in Staphylococcus aureus bacteremia. Am J Med. 1986;81(1):43–52.
12. Mylotte JM, McDermott C. Staphylococcus aureus bacteremia caused by
infected intravenous catheters. Am J Infect Control. 1987;15(1):1–6.
13. Mylotte JM, McDermott C, Spooner JA. Prospective study of 114
consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis.
1987;9(5):891–907.
14. Ehni WF, Reller LB. Short-course therapy for catheter-associated
Staphylococcus aureus bacteremia. Arch Intern Med. 1989;149(3):533–6.
15. Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related
Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin
Infect Dis Off Publ Infect Dis Soc Am. 1992;14(1):75–82.
16. Zeylemaker MM, Jaspers CA, van Kraaij MG, Visser MR, Hoepelman IM. Long-
term infectious complications and their relation to treatment duration in
catheter-related Staphylococcus aureus bacteremia. Eur J Clin Microbiol
Infect Dis. 2001;20(6):380–4.
17. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical
practice guidelines by the Infectious Diseases Society of America for the
treatment of methicillin-resistant Staphylococcus aureus infections in adults
and children. Clin Infect Dis. 2011;52(3):e18–55.
18. Shopsin B, Gomez M, Montgomery SO, Smith DH, Waddington M, Dodge
DE, et al. Evaluation of protein A gene polymorphic region DNA sequencing
for typing of Staphylococcus aureus strains. J Clin Microbiol. 1999;37(11):
3556–63.
19. Larsen AR, Stegger M, Sørum M. spa typing directly from a mecA, spa and
pvl multiplex PCR assay-a cost-effective improvement for methicillin-
resistant Staphylococcus aureus surveillance. Clin Microbiol Infect. 2008;
14(6):611–4.
20. Stammler Jaliff B, Dahl-Knudsen J, Petersen A, Skov R, Benfield T. Outcome
and reinfection after Staphylococcus aureus bacteraemia in individuals with
and without HIV-1 infection: a case–control study. BMJ Open. 2014;4(4):
e004075.
21. Kaasch AJ, Fätkenheuer G, Prinz-Langenohl R, Paulus U, Hellmich M, Weiß V,
et al. Early oral switch therapy in low-risk Staphylococcus aureus
bloodstream infection (SABATO): study protocol for a randomized
controlled trial. Trials. 2015;16:450.
Thorlacius-Ussing et al. Trials          (2019) 20:250 Page 8 of 8
